Enzo Biochem acquires Assay Designs for $12.2mm cash
Deal summary reprinted from Strategic Transactions - March 2009
Enzo Biochem has acquired privately held Assay Designs (research products) for $12.2mm in cash. Assay will become part of Enzo's gene analysis division Enzo Life Sciences. Find out more...
Deal summary reprinted from Strategic Transactions - March 2009
The transaction builds up Enzo's portfolio, fitting in nicely with the Alexis and Biomol brands, and helps Enzo better position itself in the diagnostics and scientific/medical research markets. Serving the biotech, pharma, and life science industries, Assay produces luminescent reagents as well as specialty immunological and biochemical protein detection kits--including eicosanoid, human and mouse cytokine, and nonradioactive Cox activity kits--that identify and quantify small molecules and proteins involved in inflammation, immunity, oxidative and cellular stress, steroid and hormone biology, cell signaling, and bioenergetics. The company's annual revenues surpass $11mm. The last time Assay made any waves in dealmaking was 2005, when it bought Stressgen Bioreagents from Ampersand Ventures. That acquisition brought Assay an additional line of heat shock proteins, plus ELISA kits, antibodies, recombinant proteins, and reagents.
Find out more about what our Strategic Transactions - The Device Deal Database can do for you.
Strategic Transactions - The Device Deal Database provides expanded information, including:
- Comprehensive Deal Records
- Complete Financial Information
- Extensive Company Profiles
- Access to important SEC Documents
- Links to related articles
Contact: James DeFalco at: +1 (203) 838-4401 x104 or [email protected].
